论文部分内容阅读
目的探讨替比夫定联合拉米夫定联合治疗艾滋病(获得性免疫缺陷综合征)的安全性。方法选取该院2005年3月-2009年5月收治的艾滋病患者30例,随机分为观察组和对照组各15例。对照组患者给予替比夫定600mg口服,每天1次;观察组患者在对照组治疗方案的基础上,加用拉米夫定100mg口服,每天1次。2组疗程均为1年,随访并定期监测患者血清CD+4T淋巴细胞数及不良反应。结果治疗后2组患者的CD+4细胞数均有明显增加,且观察组增加幅度明显大于对照组,差异有统计学意义(P<0.05)。2组患者在服药初期均无严重的胃肠道不适的症状及中枢神经系统症状等不良反应发生。结论替比夫定联合拉米夫定治疗艾滋病有一定疗效,能重建部分免疫功能,无严重不良反应发生,安全性较高,值得推广到临床治疗中。
Objective To investigate the safety of telbivudine combined with lamivudine in the treatment of AIDS (Acquired Immunodeficiency Syndrome). Methods Thirty patients with AIDS who were admitted to our hospital from March 2005 to May 2009 were randomly divided into observation group (15 cases) and control group (15 cases). Patients in the control group were given telbivudine 600mg orally once daily. The patients in the observation group were treated with lamivudine 100mg orally once daily on the basis of the control group. The two groups were treated for 1 year, followed up and regular monitoring of serum CD 4 T lymphocytes and adverse reactions. Results After treatment, the number of CD + 4 cells in both groups increased significantly, and the increase in the observation group was significantly greater than that in the control group (P <0.05). The patients in the two groups had no serious gastrointestinal discomfort symptoms and central nervous system symptoms during the initial medication. Conclusion telbivudine combined with lamivudine treatment of AIDS has a certain effect, to reconstruct some immune function, no serious adverse reactions, safety is high, it is worth to be extended to clinical treatment.